Predictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials.

Autor: Nebangwa, Derrick Neba1 (AUTHOR) neba.nebangwa@ubuea.cm, Shey, Robert Adamu1,2 (AUTHOR), Shadrack, Daniel Madulu3 (AUTHOR), Shintouo, Cabirou Mounchili1 (AUTHOR), Yaah, Ntang Emmaculate1 (AUTHOR), Yengo, Bernis Neneyoh4 (AUTHOR), Efeti, Mary Teke1 (AUTHOR), Gwei, Ketura Yaje1 (AUTHOR), Fomekong, Darling Bih Aubierge5 (AUTHOR), Nchanji, Gordon Takop2,6 (AUTHOR), Lemoge, Arnaud Azonpi7 (AUTHOR), Ntie‑Kang, Fidele8,9,10 (AUTHOR) stephen.ghogomu@ubuea.cm, Ghogomu, Stephen Mbigha1 (AUTHOR) fidele.ntie-kang@ubuea.cm
Zdroj: PLoS ONE. 10/21/2024, Vol. 19 Issue 10, p1-29. 29p.
Databáze: Academic Search Ultimate
Nepřihlášeným uživatelům se plný text nezobrazuje